Prof. Eva Corey
University of
Washington, USA
Email: ecorey@u.washington.edu
Qualifications
1989 Ph.D.,
Czechoslovak Academy of Sciences, Czechoslovakia
1987 M.Sc., Charles
University, Czechoslovakia
1985 B.Sc., Charles
University, Czechoslovakia
Publications (selected)
-
Corey E,
Buhler KR, Vessell’a RL. Cross-reactivity of ten anti-prostate-specific antigen
monoclonal antibodies with human glandular kallikrein. Urology 1997:50;567-572.
-
Corey E,
Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CFY, Ellis WJ, Vessella RL.
Detection of circulating prostate cells by reverse transcriptase-polymerase
chain reaction (RT-PCR) of human glandular kallikrein (hK2) and
prostate-specific antigen (PSA) messages. Urology 1997:50;184-188.
-
Corey E,
Wegner SK, Stray JE, Corey MJ, Arfman EW, Lange PH, Vessella RL. Characterization
of ten new monoclonal antibodies against prostate-specific antigen by affinity,
specificity and function in sandwich assays. Int J Cancer
1997;71:1019-1028.
-
Corey E,
Wegner SK, Corey MJ, Vessella RL. Prostate-specific antigen: Characterization
of epitopes by synthetic peptide mapping and inhibition studies. Clin
Chem 1997;43:575-584.
-
Gersuk GM,
Corey MJ, Corey E, Stray EJ, Kawasaki GH, Vessella RL. High-affinity
peptide ligands to prostate-specific antigen (PSA) identified by polysome
selection. Biochem Biophys Res Commun 1997;32:578-582.
-
Corey E,
Arfman EW, Liu AY, Vessella RL. Improved reverse
transcriptase-polymerase chain reaction protocol with exogenous internal
control for prostate-specific antigen mRNA in blood and bone marrow. Clin
Chem 1997; 3:443-452.
-
Melchior SW,
Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, Lange PH, Vessella RL. Early
tumor cell dissemination in patients with clinically localized carcinoma of the
prostate. Clin Cancer Res 1997;3:249-256.
-
Liu AY, Corey
E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS, Hood L. Identification
of differentially expressed prostate genes: Increased expression of
transcription factor ETS-2 in prostate cancer. Prostate 1997;30:145-153.
-
Corey E and
Corey MJ. Detection of disseminated prostate cells by RT-PCR: Technical and
clinical aspects. Int J Cancer 1998;77: 655-673.
-
Corey E,
Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CFY, Ellis WJ, and Vessella
RL. Detection of circulating prostate cells by reverse transcriptase-polymerase
chain reaction (RT-PCR) of human glandular kallikrein (hK2) and
prostate-specific antigen (PSA) messages. Urology 1997;50:184-188.
-
Ellis WJ,
Vessella RL, Corey E, Arfman EW, Oswin MM, Melchior SW, and Lange PH. The value
of a reverse-transcriptase polymerase chain reaction assay in patients with
prostate cancer. J Urol 1998;159:1134-1138.
-
Corey E, Brown
LG, Corey MJ, Buhler KR, and Vessella RL. The LNCaP prostate cancer cell line
produces both putative zymogen and inactive, free form of prostate specific
antigen. Prostate 1998;35:135-143.
-
Corey E and
Corey M. RT-PCR detection of prostate cells. Int J Cancer 1998;77:655-673.
-
Buhler KR,
Corey E, Stray JE, and Vessella RL. Study of free and complexed prostate
specific antigen in mice bearing human prostate cancer xenograft. Prostate
1998;6:194-200.
-
Brown JM,
Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, and Vessella RL. Osteoprotegerin
and osteoclast differentiation factor expression in prostate cancer. Urology
2001;57: 611-616.
-
Brown JM,
Kostenuik PJ, Dunstan CR, Vessella RL, and Corey E. Serum osteoprotegerin
levels are elevated in patients with advanced prostate cancer. Clin Cancer Res
2001;10:2977-2983.
-
Corey E, Quinn
JE, Vessella RL, Buhler KR, Roudier M, Brown LG, Brown JM, and Bladou F.
Establishment and characterization of osseous prostate cancer model: direct
intratibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
-
Corey E, Quinn
JE, Buhler KR, Brown LG, and Vessella RL. Inhibition of androgen-independent
growth of prostate cancer estradiol. bxenografts by 17 Clin Cancer Res
2002;8:1003-100-107.
-
Corey E, Brown
LG, Quinn JE, Poot M, Roudier MP, Higano CS, and Vessella RL. Zoledronic acid
exhibits anti-tumor effects on prostate cancer cells in vivo. Clin Cancer Res
2003 1: 295-306.
-
Brubaker KD,
Thomas R, Vessella RL, True LD, and Corey E. Expression and activity of
Cathepsin K in prostate cancer. J Bone Min Res 2003;18:222-230.
-
Corey E, Quinn
JE, Buhler KR, Nelson PS, Machoska JA, True LD, and Vessella RL. LuCaP
35 : a new model of prostate cancer progression to
androgen independence. Prostate 2003;55:239-246. (ISI: 46 citations)
-
Pfitzenmaier
J, Vessella RL, Higano CS, Noteboom J, Walace D.Jr., and Corey E. Advanced
prostate cancer patients present with elevated levels of cytokines. Cancer
2003;97:211-1216.
-
Wang Z, Corey
E, Hass GM, Higano CS, True LD, Wallace D, Konicek BW, Tisdale MJ, and Vessella
RL. Expression of the human cachexia-associated protein (HCAP) in prostate
cancer and in a prostate cancer animal model of cachexia. Int J Cancer
2003;105:123-129.
-
Brubaker KD,
Brown LG, Vessella RL, and Corey E. Osteoblast specific factor runx-2 is
expressed in prostate cancer. Prostate 2003;56:13-22. (ISI:38 citations)
-
Corey E, Quinn
JE, and Vessella RL. A novel method of generating prostate cancer metastases
from orthotopic implants. Prostate 2003;56:110-114.
-
Pfitzenmaier
J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, and Corey E.
Characterization of C4-2 prostate cancer bone metastases and their response to
castration. J Bone Min Res 2003;18:1882-1888.
-
Brubaker KD,
Corey E, Brown LG, and Vessella RL. Bone morphogenetic protein signaling in
prostate cancer cell lines. J Cell Biochem 2003;91:151-160.
-
Roudier MP,
Corey E, True LD, Higano Cs, Ott SM, Vessella RL. Histological,
immunophenotypic and histomorphometric characterization of prostate cancer bone
metastases. Cancer Treat Res 2004;118:311-339.
-
Lai JS, Brown
LG, True LD, Hawley SJ, Etzioni RS, Higano CS, Ho SM, Vessella, RL, and Corey
E. Metastases of prostate cancer express estrogen receptor beta. Urology
2004;64:814-820. (ISI:23 citations)
-
Kiefer JA,
Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR,
and Corey E. The effects of osteoprotegerin administration on the intra-tibial
growth of the osteoblastic LuCaP23.1 prostate cancer xenograft. Clin Exp
Metastasis 2004;21:381-387.
-
Corey E, Brown
LG, Kiefer JA, Quinn JE, Pitts TM, Blair JM, and Vessella RL. Osteoprotegerin
in prostate cancer bone metastasis. Cancer Res 2005;65:1710-1718.
-
Brown JE,
Brown LG, Zhang J, Keller ET, Corey E. Comparison of Fc-osteoprotegerin and
zoledronic acid activities suggests that zoledronic acid inhibits prostate
cancer in bone by indirect mechanisms. Prostate Cancer and Prostatic Diseases
2005;8:253-259.
-
Stangelberger
A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E,
and Vessella R. Targeted chemotherapy with cytotoxic bombesin analoque AN-215
inhibits growth of experimental human prostate cancers. Int J Cancer
2006;118:222-9.
-
Brubaker KD,
Brown LG, Vessella RL and Corey E. Administration of zoledronic acid enhances
the effects of docetaxel on growth of prostate cancer in the bone environment.
BMC Cancer 2006;6:15.
-
Coleman IM,
Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey
E. Inhibition of androgen-independent prostate cancer by estrogenic compounds
is associated with the increased expression of immune-related genes. Neoplasia
2006;8:862-78.
-
Vessella RL
and Corey E. Targeting factors involved in bone remodeling as treatment
strategies in prostate cancer bone metastasis. Clin Cancer Res
2006;12:6285s-6290s.
-
Guise TA,
Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella RL, Corey E,
Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic
and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6216s.
-
Corey E. Estrogen
and prostate: Friend or foe. Current Cancer Therapy Reviews 2006;2:341-351.
-
Emami KH and
Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett
2007;253:170-179.
-
Morrissey CM,
Kostenuik PJ, Brown LG, Vessella RL, Corey E. Host-Derived RANKL is
Responsible for Osteolysis in C4-2 Human Prostate Cancer Xenograft Model of
Experimental Bone Metastases. BMC Cancer 2007;7:148.
-
Johnen H, Lin
S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L,
Junankar S, Hunter M, Fairlie WD, Lee NJ, Enriquez RF, Baldock PA, Corey E,
Apple FS, Murakami MM, Lin EJ, Wang C, During MJ, Sainsbury A, Herzog H, Breit
SN. Tumor-induced anorexia and weight loss are mediated by the TGF-beta
superfamily cytokine MIC-1. Nat Med, 2007, 13:1333-1340.
-
Morgan TN,
Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001
(Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory
effects are increased by combination with docetaxel and zoledronic acid. Prostate.
2008; 68:861-871.
-
Morrissey C,
True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey
E, Lange PH, Higano CS, Vessella RL. Differential expression of
angiogenesis associated genes in prostate cancer bone, liver and lymph node
metastases. Clin Exp Metastasis 2008, 25:377-388.
-
Morgan TM,
Koreckij T, Corey E. Targeted therapy for advanced prostate cancer: inhibition
of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009;9:237-249.
PMC2921605
-
Trauger R,
Corey E, Bell D, White S, Garsd A, Stickney D, Reading C, Frincke J. Inhibition
of androstenediol-dependent LNCaP tumour growth by
17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235). Br J Cancer.
2009;10:1068-1072. PMC2669987